Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials

Halimatou Diawara(Université des Sciences, des Techniques et des Technologies de Bamako), Amatigué Zéguimé, Alassane Dicko(University of Bamako), Natasha KC(Sanaria), Tooba Murshedkar(Sanaria), Ibrahim H. Soumbounou, Thomas L. Richie(Sanaria), Zonghui Hu(National Institutes of Health), Santara Gaoussou(University of Bamako), Djibrilla Issiaka, Rathy Mohan(National Institutes of Health), Patrick E. Duffy(National Institute of Allergy and Infectious Diseases), Irfan Zaidi(National Institutes of Health), Blair J. Wylie(Columbia University Irving Medical Center), Seydou Traoré, Justin Doritchamou(National Institutes of Health), Oumar Attaher(University of Bamako), Michal Fried(National Institutes of Health), Agnes Mwakingwe-Omari(National Institutes of Health), Sara A. Healy(National Institutes of Health), Viyada Doan(National Institutes of Health), Jing Wang(Peking University), Kelly M. Rausch(National Institutes of Health), Almahamoudou Mahamar(Centre National de la Recherche Scientifique), Peter F. Billingsley(Sanaria), B Kim Lee Sim(Sanaria), Robert Morrison(National Institutes of Health), Amagana Dolo(University of Bamako), Stephen L. Hoffman(University of Maryland, Baltimore), Aye Diallo(National Institutes of Health)
The Lancet Infectious Diseases
August 14, 2024
Cited by 31


Related Papers